Glenmark Pharmaceuticals announced Friday that its US subsidiary has begun commercial distribution of progesterone vaginal inserts 100mg, the generic equivalent of Ferring Pharmaceuticals' Endometrin, following final approval from the US Food and Drug Administration confirmed on April 9, 2026. The launch marks a significant entry into the assisted reproductive technology market, where progesterone supplementation is a standard component of IVF protocols.

The approval, granted under an Abbreviated New Drug Application, positions Glenmark to compete directly with branded Endometrin across fertility clinics and specialty pharmacies nationwide. Analysts estimate the US progesterone vaginal insert market generates approximately $200 million annually, with demand concentrated among the roughly 400,000 IVF cycles performed in the United States each year.

Glenmark's North America President stated that the company had pre-positioned inventory in anticipation of final clearance and that fulfillment to specialty pharmacy partners and fertility practice networks would begin immediately. The company cited competitive pricing as a key differentiator, noting that generic availability could reduce out-of-pocket costs for patients, a significant concern given that fertility treatments are often not covered by insurance.

Fertility specialists and reproductive endocrinologists reached for comment noted that a competitively priced generic option is clinically welcome, as progesterone support during the luteal phase is non-negotiable in frozen embryo transfer cycles. The American Society for Reproductive Medicine has previously flagged drug cost barriers as a meaningful obstacle to equitable fertility care access in the United States.

The launch adds to Glenmark's expanding women's health portfolio in North America and follows a period of strategic investment by the Mumbai-based company in complex generics and specialty formulations. Market watchers expect at least one additional generic entrant in the progesterone insert space within 12 months, which could further compress pricing and broaden patient access.